Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JANX007 + darolutamide
- Development stage
- Phase 1
- Lead developer
- Janux Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JANX007 + darolutamide is a combination investigational regimen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) currently in Phase 1 clinical studies. JANX007 is a targeted immunotherapy developed by Janux Therapeutics, designed as a prostate-specific membrane antigen (PSMA) T-cell engager that recruits and activates T cells in the tumor microenvironment to kill PSMA-expressing tumor cells, while darolutamide is an approved small molecule nonsteroidal androgen receptor antagonist that inhibits androgen receptor signaling, blocking the growth and survival of prostate cancer cells. The combination aims to target prostate cancer cells through complementary mechanisms—direct androgen receptor antagonism (darolutamide) and immune-mediated cytotoxicity (JANX007)[3][5][7].
- Other names
- BAY1841788BAY-1841788BAY 1841788ODM-201ODM201ODM 201
02
Targets
AR (Adrenergic receptors)CD3 (T-cell surface glycoprotein CD3)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on JANX007 + darolutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JANX007 + darolutamide.